Mohini Ranganathan is a Psychiatry physician affiliated with Yale University. OpenAlex indexes 135 publications with 5,978 citations (h-index 42); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
950 Campbell Ave
Psychiatry Service/116a
West Haven, CT 065162770
Telephone
203-932-5711Registry record last updated 21 Feb 2008.
Clinical trials
- FAAH Availability in Psychiatric Disorders: A PET Study
Sponsor: Yale University
- BXCL501 for Agitation in Schizophrenia
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Lithium100%Lithium Carbonate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2011–2023 per NIH RePORTER. The latest:
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Yale University
FY2023$51,979R21AT010763 - Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
Yale University
FY2020$221,251R21AT010763 - Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization
Yale University
FY2020$209,375R21AT010763
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
The World Journal of Biological Psychiatry
2022
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Thomas McGlashan, MD
Yale University
Charles Nemeroff, MD
Dell Medical School
Maurizio Fava, MD
Massachusetts General Hospital
John Krystal, MD
Yale University
Raquel Gur, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”